Myricx Bio: Funding, Investors & Team (Oct 2026)
Myricx Bio is a company specializing in discovering small molecule drugs, specifically inhibitors of N-myristoyl transferase (NMT), which is crucial for cancer cell survival. They are primarily focused on oncology but are also looking at other potential uses for their proprietary inhibitors. Myricx Bio is developing a pipeline of ADCs that use their NMT inhibitor as a payload, showing promising results in preclinical studies for various solid tumors and cancer cell types.
Myricx Bio has raised $115M across 1 funding round on record, the most recent a Series A of $115M announced in Jul 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Myricx Bio Company Profile and Key Stats
Latest funding round on record: Jul 2024.
Myricx Bio Funding Rounds
Myricx Bio Founders and Leadership Team
Contact details for the Myricx Bio team: 1 of 1 has an email address on file.
Start 14-day free trial →Myricx Bio Funding Compared to Other Biotechnology Startups
Myricx Bio's latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Myricx Bio in Biotechnology and London
Companies Similar to Myricx Bio
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
Myricx Bio Funding FAQs
What does Myricx Bio do?
Myricx Bio is a company specializing in discovering small molecule drugs, specifically inhibitors of N-myristoyl transferase (NMT), which is crucial for cancer cell survival. They are primarily focused on oncology but are also looking at other potential uses for their proprietary inhibitors. Myricx Bio is developing a pipeline of ADCs that use their NMT inhibitor as a payload, showing promising results in preclinical studies for various solid tumors and cancer cell types.
How much funding has Myricx Bio raised?
Myricx Bio has raised $115M across 1 round on record. The most recent is a Series A of $115M announced in Jul 2024.
When did Myricx Bio last raise funding?
Myricx Bio's most recent funding round on record is a Series A of $115M, announced in Jul 2024.
Who founded Myricx Bio?
FundedIQ lists Ed Tate (Founder) at Myricx Bio.
Where is Myricx Bio headquartered?
Myricx Bio is based in London, England, United Kingdom.
How many employees does Myricx Bio have?
Myricx Bio is in the 1-10 employee band.
How does Myricx Bio's funding compare to other Biotechnology startups?
Myricx Bio's latest round of $115M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Myricx Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Myricx Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.